Effect of ultrasound transmit power on liver enhancement with imagent® US, a PFC-stabilized microbubble contrast agent

Claude B. Sirlin, Michael S. Girard, Gregory C. Steinbach, Kristine G. Baker, Susan K. Broderdorf, Lisa A. Hall, Robert F. Mattrey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The pressure of the ultrasound wave may limit the longevity of microbubble-based contrast agents. This study evaluated liver enhancement over time as a function of transmit power after the administration of AFO145 (Imagent® US; Alliance Pharmaceutical Corp., San Diego, CA). Eight rabbits with an avascular liver lesion created by percutaneous injection of 1.0 ml of ethyl alcohol 7 days prior to scanning were imaged with an Acuson 128XP/10 at 7 MHz before and after four separate intravenous injections of 0.25 ml of AFO145 spaced at least 1 h apart. The avascular lesion served as an internal standard against which liver enhancement could be compared. After contrast injection, scanning over the same plane was either continuous at (a) maximum or (b) minimum transmit power (9 dB below maximum), or intermittent at (c) minimum power for 5 s every 15 s, or (d) for 5 s every 60 s. Each session was terminated after 15 min or when contrast was no longer visible in the hepatic parenchyma and blood vessels. Videodensitometry was used to assess liver-to-lesion intensity difference over time. Both the degree and duration of liver enhancement were dependent on the transmit power. Liver enhancement with imaging at minimum power for 5 s/min was nearly two times greater and persisted nearly eight times longer (P < 0.01) than at maximum power and continuous insonation. Ultrasound transmit power affects both the peak and duration of liver enhancement. A lower power and shorter insonation time after AFO145 administration dramatically lengthens the imaging window for liver lesion detection.

Original languageEnglish (US)
Pages (from-to)82-88
Number of pages7
JournalInternational Journal of Imaging Systems and Technology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint

Liver
Contrast Media
Ultrasonics
Scanning
Imaging techniques
Imagent US
Blood vessels
Drug products
Ethanol
Pharmaceutical Preparations

Keywords

  • Contrast media
  • Liver enhancement
  • Microbubbles
  • Transmit power
  • Ultrasound

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Software
  • Computer Vision and Pattern Recognition
  • Electrical and Electronic Engineering

Cite this

Effect of ultrasound transmit power on liver enhancement with imagent® US, a PFC-stabilized microbubble contrast agent. / Sirlin, Claude B.; Girard, Michael S.; Steinbach, Gregory C.; Baker, Kristine G.; Broderdorf, Susan K.; Hall, Lisa A.; Mattrey, Robert F.

In: International Journal of Imaging Systems and Technology, Vol. 8, No. 1, 01.01.1997, p. 82-88.

Research output: Contribution to journalArticle

Sirlin, Claude B. ; Girard, Michael S. ; Steinbach, Gregory C. ; Baker, Kristine G. ; Broderdorf, Susan K. ; Hall, Lisa A. ; Mattrey, Robert F. / Effect of ultrasound transmit power on liver enhancement with imagent® US, a PFC-stabilized microbubble contrast agent. In: International Journal of Imaging Systems and Technology. 1997 ; Vol. 8, No. 1. pp. 82-88.
@article{13cf3232162c4305a9f2e9111ecbbf10,
title = "Effect of ultrasound transmit power on liver enhancement with imagent{\circledR} US, a PFC-stabilized microbubble contrast agent",
abstract = "The pressure of the ultrasound wave may limit the longevity of microbubble-based contrast agents. This study evaluated liver enhancement over time as a function of transmit power after the administration of AFO145 (Imagent{\circledR} US; Alliance Pharmaceutical Corp., San Diego, CA). Eight rabbits with an avascular liver lesion created by percutaneous injection of 1.0 ml of ethyl alcohol 7 days prior to scanning were imaged with an Acuson 128XP/10 at 7 MHz before and after four separate intravenous injections of 0.25 ml of AFO145 spaced at least 1 h apart. The avascular lesion served as an internal standard against which liver enhancement could be compared. After contrast injection, scanning over the same plane was either continuous at (a) maximum or (b) minimum transmit power (9 dB below maximum), or intermittent at (c) minimum power for 5 s every 15 s, or (d) for 5 s every 60 s. Each session was terminated after 15 min or when contrast was no longer visible in the hepatic parenchyma and blood vessels. Videodensitometry was used to assess liver-to-lesion intensity difference over time. Both the degree and duration of liver enhancement were dependent on the transmit power. Liver enhancement with imaging at minimum power for 5 s/min was nearly two times greater and persisted nearly eight times longer (P < 0.01) than at maximum power and continuous insonation. Ultrasound transmit power affects both the peak and duration of liver enhancement. A lower power and shorter insonation time after AFO145 administration dramatically lengthens the imaging window for liver lesion detection.",
keywords = "Contrast media, Liver enhancement, Microbubbles, Transmit power, Ultrasound",
author = "Sirlin, {Claude B.} and Girard, {Michael S.} and Steinbach, {Gregory C.} and Baker, {Kristine G.} and Broderdorf, {Susan K.} and Hall, {Lisa A.} and Mattrey, {Robert F.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1002/(SICI)1098-1098(1997)8:1<82::AID-IMA10>3.0.CO;2-N",
language = "English (US)",
volume = "8",
pages = "82--88",
journal = "International Journal of Imaging Systems and Technology",
issn = "0899-9457",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of ultrasound transmit power on liver enhancement with imagent® US, a PFC-stabilized microbubble contrast agent

AU - Sirlin, Claude B.

AU - Girard, Michael S.

AU - Steinbach, Gregory C.

AU - Baker, Kristine G.

AU - Broderdorf, Susan K.

AU - Hall, Lisa A.

AU - Mattrey, Robert F.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The pressure of the ultrasound wave may limit the longevity of microbubble-based contrast agents. This study evaluated liver enhancement over time as a function of transmit power after the administration of AFO145 (Imagent® US; Alliance Pharmaceutical Corp., San Diego, CA). Eight rabbits with an avascular liver lesion created by percutaneous injection of 1.0 ml of ethyl alcohol 7 days prior to scanning were imaged with an Acuson 128XP/10 at 7 MHz before and after four separate intravenous injections of 0.25 ml of AFO145 spaced at least 1 h apart. The avascular lesion served as an internal standard against which liver enhancement could be compared. After contrast injection, scanning over the same plane was either continuous at (a) maximum or (b) minimum transmit power (9 dB below maximum), or intermittent at (c) minimum power for 5 s every 15 s, or (d) for 5 s every 60 s. Each session was terminated after 15 min or when contrast was no longer visible in the hepatic parenchyma and blood vessels. Videodensitometry was used to assess liver-to-lesion intensity difference over time. Both the degree and duration of liver enhancement were dependent on the transmit power. Liver enhancement with imaging at minimum power for 5 s/min was nearly two times greater and persisted nearly eight times longer (P < 0.01) than at maximum power and continuous insonation. Ultrasound transmit power affects both the peak and duration of liver enhancement. A lower power and shorter insonation time after AFO145 administration dramatically lengthens the imaging window for liver lesion detection.

AB - The pressure of the ultrasound wave may limit the longevity of microbubble-based contrast agents. This study evaluated liver enhancement over time as a function of transmit power after the administration of AFO145 (Imagent® US; Alliance Pharmaceutical Corp., San Diego, CA). Eight rabbits with an avascular liver lesion created by percutaneous injection of 1.0 ml of ethyl alcohol 7 days prior to scanning were imaged with an Acuson 128XP/10 at 7 MHz before and after four separate intravenous injections of 0.25 ml of AFO145 spaced at least 1 h apart. The avascular lesion served as an internal standard against which liver enhancement could be compared. After contrast injection, scanning over the same plane was either continuous at (a) maximum or (b) minimum transmit power (9 dB below maximum), or intermittent at (c) minimum power for 5 s every 15 s, or (d) for 5 s every 60 s. Each session was terminated after 15 min or when contrast was no longer visible in the hepatic parenchyma and blood vessels. Videodensitometry was used to assess liver-to-lesion intensity difference over time. Both the degree and duration of liver enhancement were dependent on the transmit power. Liver enhancement with imaging at minimum power for 5 s/min was nearly two times greater and persisted nearly eight times longer (P < 0.01) than at maximum power and continuous insonation. Ultrasound transmit power affects both the peak and duration of liver enhancement. A lower power and shorter insonation time after AFO145 administration dramatically lengthens the imaging window for liver lesion detection.

KW - Contrast media

KW - Liver enhancement

KW - Microbubbles

KW - Transmit power

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0030849580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030849580&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-1098(1997)8:1<82::AID-IMA10>3.0.CO;2-N

DO - 10.1002/(SICI)1098-1098(1997)8:1<82::AID-IMA10>3.0.CO;2-N

M3 - Article

AN - SCOPUS:0030849580

VL - 8

SP - 82

EP - 88

JO - International Journal of Imaging Systems and Technology

JF - International Journal of Imaging Systems and Technology

SN - 0899-9457

IS - 1

ER -